EPICO PROJECT. Development of educational recommendations using the delphi technique on invasive candidiasis in non-neutropenic critically ill adult patients;PROYECTO ÉPICO. Desarrollo de unas recomendaciones educacionales mediante metodología delphi en pacientes críticos adultos no neutropénicos con candidiasis invasiva

Revista Espanola de Quimioterapia

Volumn 26, Issue 2, 2013, Pages 131-150

  Zaragoza, Rafael ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Delphi technique; Educational project; Invasive candidiasis; Non neutropenic critically ill patients; Recommendations

Indexed keywords

FLUCONAZOLE; TRIAZOLE;

BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA SCORE; CANDIDA TROPICALIS; CRITICALLY ILL PATIENT; DELPHI STUDY; HEALTH SURVEY; HUMAN; INVASIVE CANDIDIASIS; MEDICAL SPECIALIST; MICROBIAL COLONIZATION; NEUTROPENIA; NONHUMAN; PROFESSIONAL KNOWLEDGE; REVIEW; SCORING SYSTEM;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, INVASIVE; CONSENSUS; CRITICAL ILLNESS; DELPHI TECHNIQUE; ECHINOCANDINS; EYE DISEASES; FLUCONAZOLE; GUIDELINES AS TOPIC; HUMANS; NEUTROPENIA; REFERRAL AND CONSULTATION; RISK FACTORS; SPAIN;

EID: 84890417382     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Aguado JM, Ruiz-Camps I, Muñoz P, Mensa J, Almirante B, Vázquez L, et al. Recomendaciones sobre el tratamiento de la candidiasis invasora y otras infecciones por levaduras de la Sociedad Española de Enfermedades Infecciosas y Microbiología clínica (SEIMC). Actualización 2011. Enferm Infecc Microbiol Clin 2011; 29: 345-61.
2. Alam FF, Mustafa AS, Khan ZU. Comparative evaluation of (1, 3)-beta-D-glucan, mannan and anti-mannan antibodies, and Candida species-specific snPCR in patients with candidemia. BMC Infect Dis 2007; 7: 103.
3. Acosta J, Catalán M, Del-Palacio-Perez-Medel A, Montejo JC, De-LaCruz-Bertolo J, Moragues MD, et al. Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)-beta-D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease. Eur J Clin Microbiol Infect Dis 2012; 31: 721-31.
4. Arendrup MC. Epidemiology of invasive candidiasis. Curr Opin Crit Care 2010; 16: 445-52.
5. Vincent JL, Anaissie E, Bruining H, Demajo W, El-Ebiary M, Haber J et al. Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. Intensive Care Med 1998: 24: 206-16.
6. Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006; 6: 21.
7. Almirante B, Rodríguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, et al, Barcelona Candidemia Project Study-Group. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005; 43: 1829-35.
8. Bouza E, Muñoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 2008; 32 (Suppl 2):S87-91.
9. Pemán J, Cantón E, Quindós G, Eraso E, Alcoba J, Guinea J, et al on behalf of the FUNGEMYCA Study Group. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. J Antimicrob Chemother 2012; 67: 1181-7.
10. Leroy O, Mira JP, Montravers P, Gangneux JP, Lortholary O; AmarCand Study Group. Comparison of albicans vs. non-albicanscandidemia in French intensive care units. Crit Care 2010; 14(3): R98.
11. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-9.
12. Dimopoulos G, Karabinis A, Samonis G, Falagas ME. Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. Eur J Clin Microbiol Infect Dis 2007; 26: 377-84.
13. Playford EG, Nimmo GR, Tilse M, Sorrell TC. Increasing incidence of candidaemia: long-term epidemiological trends, Queensland, Australia, 1999-2008. J Hosp Infect 2010; 76: 46-51.
14. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18 Suppl 7:19-37.
15. Pappas PG, Kauffman CA, Andes D, Benjamin Jr. DK, Calandra TF, Edwards Jr. JE, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
16. Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S. Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother 2005; 56: 532-7.
17. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009; 37: 1612-8.
18. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. EPIC II Group of Investigators. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323-9.
19. Kett DH, Azoulay E, Echeverria PM, Vincent JL. Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011; 39: 665-70.
20. Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH, et al. Australian Candidemia Study, Australasian Society for Infectious Diseases.Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010; 65: 1042-51.
21. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 2009; 115: 4745-52.
22. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009). Diagn Microbiol Infect Dis 2010; 68: 278-83.
23. Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, Ruiz Pérez de Pipaón M, Hernández-Caballero C, et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010; 54: 3149-54.
24. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
25. Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of Antifungal Therapy Timing on Mortality in Cancer Patients with Candidemia. Antimicrobial Agents and Chemotherapy 2009; 54: 184-90.
26. Andes DR, Safdar N, Baddley JW, Playford G, Reboli AC, Rex JH, et al. Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials. Clin Infect Dis 2012; 54: 1110-22.
27. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48: 1695-703.
28. Fernandez Cruz A, Menarquez M, Pedromingo M, Pelaez T, Solis J, Rodriguez-Creixems M, et al. Candida Endocarditis: Yield of Echocardiogram in Patients with Candidemia. K 2172; ICAAC 2010.
29. Marriott DJ, Playford EG, Chen S, Slavin M, Nguyen Q, Ellis D, et al. Australian Candidaemia Study. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit Care 2009; 13(4): R115.
30. León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34: 730-7.
31. Agvald-Ohman C, Klingspor L, Hjelmqvist H, Edlund C. Invasive candidiasis in long-term patients at a multidisciplinary intensive care unit: Candida colonization index, risk factors, treatment and outcome. Scand J Infect Dis 2008; 40: 145.
32. Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L, et al. Assessment of pre-emptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32: 2443-9.
33. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994; 220: 751-8.
34. León C, Ruiz-Santana S, Saavedra P, Galvan B, Blanco A, Castro C, Balasini C, et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Crit Care Med 2009; 37: 1624-33.
35. Denning DW, Kibbler CC, Barnes RA; British Society for Medical Mycology. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003; 3: 230-40.
36. Cuenca-Estrella M, Verweij PE, Arendrup MC, Arikan-Akdagli S, Bille J, Donnelly JP, et al. ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. Clin Microbiol Infect 2012; 18 Suppl 7:9-18.
37. Pemán J, Zaragoza R. Towards an early diagnosis of invasive candidiasis in the critically ill patient. Rev Iberoam Micol 2012; 29: 71-5.
38. Garnacho-Montero J, Díaz-Martín A, Ruiz-Pérez DePiappón M, García-Cabrera E. Invasive fungal infection in criticallyillpatients. Enferm Infecc Microbiol Clin 2012; 30: 338-43.
39. Gadea I, Cuenca-Estrella M. Recomendaciones para el diagnóstico micológico y estudios de sensibilidad a los antifúngicos. Enferm Infecc Microbiol Clin 2004; 22: 32-9.
40. Montravers P, Dupont H, Gauzit R, Veber B, Auboyer C, Blin P, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006; 34: 646-52.
41. Ubeda A, Vázquez AL, Gil CL. Candida peritonitis. Enferm Infecc Microbiol Clin 2010; 28 (Suppl 2): 42-8.
42. Zaragoza R, Pemán J, Salavert M. Is the use of antifungal management advisable in critical patients with positive isolation of Candida spp.from intraabdominal clinical samples? Rev Iberoam Micol 2008; 25: 203-7.
43. Dupont H, Paugam-Burtz C, Muller-Serieys C, Fierobe L, Chosidow D, Marmuse JP, et al. Predictive factors of mortality due to polymicrobial peritonitis with Candida isolation in peritoneal fluid in critically ill patients. Arch Surg 2002; 137: 1341-6.
44. Meersseman W, Lagrou K, Spriet I, Maertens J, Verbeken E, Peetermans WE, et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 2009; 35: 1526-31.
45. Charles PE, Dalle F, Aube H, Doise JM, Quenot JP, Aho LS et al. Candida spp. colonization significance in critically ill medical patients: A prospective study. Intensive Care Med 2005; 31: 393-400.
46. Charles PE, Dalle F, Aho S, Quenot JP, Doise JM, Aube H, et al. Serum procalcitonin measurement contribution to the early diagnosis of candidemia in critically ill patients. Intensive Care Med 2006; 32: 1577-83.
47. Martini A, Gottin L, Menestrina N, Schweiger V, Simion D, Vincent JL. Procalcitonin levels in surgical patients at risk of candidemia. J Infect 2010; 60:425-30.
48. Pemán J, Zaragoza R. Current diagnostic approaches to invasive candidiasis in critical care settings. Mycoses 2010; 53: 424-33.
49. Mikulska M, Calandra T, Sanguinetti M, Poulain D, Viscoli C. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia. Crit Care 2010; 14: R222.
50. Mohr JF, Sims C, Paetznick V, Rodriguez J, Finkelman MA, Rex JH, et al. Prospective survey of (1->3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol 2011; 49: 58-61.
51. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, et al. Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41: 654-9.
52. Zaragoza R, Pemán J, Quindós G, Iruretagoyena JR, Cuétara MS, Ramirez P, et al. Clinical significance of the detection of Candida albicans germ tube-specific antibodies in critically ill patients. Clin Microbiol Infect 2009; 15: 592-5.
53. Zaragoza R, Peman J, Quindós G, Iruretagoyena JR, Cuétara MS, Ramirez P, et al. Kinetic Patterns of Candida albicans Germ Tube Antibody (CAGTA) in Critically Ill Patients: Influence on Mortality. Clin Vaccine Immunol 2009; 16: 1527-8.
54. Klingspor L, Jalal S. Molecular detection and identification of Candida and Aspergillus spp. from clinical samples using real-time PCR. Clin Microbiol Infect 2006; 12: 745-53.
55. McMullan R, Metwally L, Coyle PV, Hedderwick S, McCloskey B, O'Neill HJ, et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis 2008; 46: 890-6.
56. Westh H, Lisby G, Breysse F, Boddinghaus B, Chomarat M, Gant V, et al. Multiplex real-time PCR and blood culture for identification of bloodstream pathogens in patients with suspected sepsis. Clin Microbiol Infect 2009; 15: 544-51.
57. Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ. A Multicenter, Double-Blind Trial of a High-Dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adults Patients with Invasive Candidiasis. Clin Infect Dis 2009; 48: 1676-84.
58. Pappas PG, Rotstein CMF, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis. Clin Infect Dis 2007; 45: 883-93.
59. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, et al. CLSI Subcommittee for Antifungal Testing. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011; 14: 164-76.
60. Kale-Pradhan PB, Morgan G, Wilhelm SM, Johnson LB. Comparative Efficacy of Echinocandins and Nonechinocandins for the Treatment of Candida parapsilosis Infections: A Meta-analysis. Pharmacotherapy 2010; 30: 1207-12.
61. Huynh N, Peggy Chang HY, Bordoli-Gerogiannis SB. Ocular Involvement in Hospitalized Patients with Candidemia: Analysis at a Boston Tertiary Care Center. Ocular Inmunology Inflammation 2012; 20: 100-03.
62. Oude Lashof AML, Rothova A, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, et al. Ocular Manifestations of Candidemia. Cin Infect Dis 2011; 53: 262-8.
63. Riddell IV J, Comer GM and Kauffman CA. Treatment of Endogenous Fungal Endophthalmitis: Focus on New Antifungal Agents. Clin Infect Dis 2011; 52: 648-53.
64. Nucci M, Anaissie E, Betts RF, Dupont BF, Wu C, Buell DN. Early Removal of Central Venous Catheter in Patients with Candidemia Does Not Improve Outcome: Analysis of 842 Patients from 2 Randomized Clinical Trial. Clin Infect Dis 2010; 51: 295-303.
65. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by Infectious Diseases Society of America. Clin Infect Dis 2009; 49: 1-45.
66. Wang JL, Chang CH, Young-Xu Y and Chang KA. Systematic Review and Meta-analysis of the Tolerability and Hepatotoxicity of Antifungals in Empirical and Definitive Therapy for Invasive Fungal Infection. Antimicrob Agent Chemother 2010; 54: 2409-19.
67. Zuluaga Rodríguez A, de Bedout Gómez C, Agudelo Restrepo CA, Hurtado Parra S, Arango Arteaga M, Restrepo Moreno A, et al Sensibilidad a fluconazol y voriconazol de especies de Candida aisladas de pacientes provenientes de unidades de cuidados intensivos en Medellín, Colombia (2001-2007). Rev Iberoam Micol 2010; 27: 125-9.
68. Collins CD, Eschenauer GA, Salo SL, Newton DW. To Test or Not To Test: a Cost Minimization Analysis of Susceptibility Testing for Patients with Documented Candida glabrata Fungemias. J Clin Microbiol 2007; 45: 1884-8.
69. Shah DN, Yau R, Weston J, Lasco TM, Salazar M, Palmer HR, et al. Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes. J Antimicrob Chemother 2011; 66: 2146-51.
70. Fukuoka T, Johnston DA, Winslow CA, de Groot MJ, Burt C, Hitchcock CA, et al. Genetic Basis for Differential Activities of Fluconazole and Voriconazole against Candida krusei. Antimicrob Agents Chemother 2003; 47: 1213-9.